Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market Size, Share, and Growth Forecast, 2026 - 2033

The global postural orthostatic tachycardia syndrome (POTS) treatment market size is likely to be valued at US$0.47 billion in 2026 and is expected to reach US$0.81 billion by 2033, growing at a CAGR of 8.0% between 2026 and 2033, driven by rising clinical recognition of POTS, an expanding Long COVID patient pool, and wider adoption of multidisciplinary care programs.

Treatment currently relies on repurposed drugs and supportive measures, as no therapy is approved by the U.S. FDA specifically for POTS, while late-stage pipeline activity is shifting attention toward targeted therapies.

Drivers - Rising Diagnosis and Long COVID-Linked Cases Are Expanding the Treated Patient Pool

Clinical recognition of POTS is improving, which is increasing the number of patients entering treatment. The Heart Rhythm Society's 2015 consensus statement placed prevalence at approximately 0.2%, with most patients presenting between 15 and 25 years of age and more than 75% being female. U.S. estimates range from 500,000 to 3,000,000 patients, partly because POTS had no dedicated diagnostic code until ICD-10-CM code G90. It took effect on October 1, 2022. A unique code supports clinical documentation, national-level research, and tracking of treated patients.

Long COVID has added a newly diagnosed population. The NIH-funded RECOVER Initiative cites 31% of people with Long COVID developing POTS, and a Karolinska Institutet study published in September 2025 identified POTS in almost one-third of 467 patients with severe Long COVID. A multicenter study across eight UK Long COVID clinics found that 7% of 277 patients met PoTS criteria. These findings are expanding orthostatic testing in Long COVID clinics.

Late-Stage Pipeline Activity and Multidisciplinary Care Models Are Broadening Treatment Options

Drug development is moving beyond repurposed cardiovascular agents. Regeneron is developing baloncibart, an NPR1 antagonist antibody, in a Phase 2 POTS study, with results planned for the American Autonomic Society meeting in November 2026 and a Phase 3 study planned for the first half of 2027, pending regulatory feedback. Academic programs are also evaluating intravenous immunoglobulin, intravenous iron, and vagus nerve stimulation.

Care models are also changing. A 2026 international multidisciplinary consensus statement, developed by 40 contributors from seven countries and published in The American Journal of Medicine, evaluated 31 guidance statements on the recognition, diagnosis, and management of POTS and non-POTS dysautonomia.

Restraint - Absence of Approved Therapies and Limited Evidence Restrict Treatment Standardization

No therapy is approved by the U.S. FDA specifically for POTS, so beta-blockers, fludrocortisone, midodrine, and ivabradine are prescribed off-label. The evidence base remains limited, as NHS Scotland's interim guidance approved in April 2026 describes the evidence for current management as notably weak. RECOVER-AUTONOMIC, the largest randomized placebo-controlled trial in the POTS and Long COVID POTS population to date, enrolled 181 adults and found that ivabradine reduced heart rate versus placebo without significantly improving patient-reported symptoms.

Cost and access add further constraints. Low-cost generics are available for the core drug classes, including AB-rated generic ivabradine launched in the United States in July 2024, which holds down per-prescription value. A 2025 PoTS UK survey reported that 90% of patients in Scotland experienced difficulty accessing NHS healthcare, and 59% said their GP had not heard of PoTS or doubted that it exists.

Opportunities - POTS-Specific and Immune-Directed Therapies Create New Opportunities Beyond Repurposed Drugs

One of the most significant opportunities in the market is the transition from repurposed drugs to therapies designed for defined POTS mechanisms. Regeneron's baloncibart targets the NPR1 pathway, which is involved in blood volume and vascular tone regulation, and is advancing toward a planned Phase 3 study.

Immune-directed approaches add a second opportunity. Autoimmune POTS is the fastest-growing subtype, supported by findings such as positive antinuclear antibodies in up to 25% of patients. Intravenous immunoglobulin is under evaluation within the RECOVER-AUTONOMIC platform and in a Dysautonomia International-funded study, while argenx has sponsored a Phase 2 trial of efgartigimod in post-COVID POTS.

Specialty Dysautonomia Clinics and Asia Pacific Offer Strong Expansion Potential

Specialty dysautonomia clinics are the fastest-growing care setting. Hospitals hold approximately 48% of the market because of tilt-table testing, infusion services, and specialist care, while dedicated POTS programs provide longitudinal, multidisciplinary management. The Calgary Autonomic Investigation and Management Clinic, which opened in 2015, illustrates the referral-based model that combines orthostatic testing, dietary guidance, and supervised exercise training.

Asia Pacific presents strong growth potential because of its large adolescent population. A large Chinese epidemiological study reported POTS prevalence of approximately 6.8% among adolescents, compared with 0.2% to 1.0% in Western estimates, while Japanese studies estimate that about 10% of junior high and high school students have orthostatic dysregulation.

Treatment Type Insights

Pharmacological treatment is anticipated to account for approximately 54.6% of the market share. It includes beta-blockers, fludrocortisone, midodrine, and ivabradine, which remain the core revenue drivers. For example, propranolol or metoprolol is prescribed to reduce orthostatic tachycardia in patients with adrenergic symptoms, fludrocortisone is used to expand blood volume, and midodrine is used to increase vascular tone. Routine off-label prescribing, low-cost generics, and the absence of approved POTS-specific alternatives continue to support segment leadership.

Non-pharmacological treatment is anticipated to be the fastest-growing treatment type, driven by consensus emphasis on multimodal management. It includes exercise and physical therapy, increased fluid and salt intake, compression garments, diet modification, and lifestyle management. For example, University of Calgary researchers published a study in the Canadian Journal of Cardiology in 2026 reporting that abdominal-only compression garments reduced orthostatic tachycardia and improved symptoms. In RECOVER-AUTONOMIC, participants receiving coordinated care alongside ivabradine reported improved symptoms compared with those receiving ivabradine and usual care, reinforcing demand for structured programs.

Drug Class Insights

Beta-blockers are anticipated to account for 32.4% of market share, widely used to control orthostatic tachycardia and adrenergic symptoms. Propranolol and metoprolol are commonly prescribed, particularly for hyperadrenergic POTS. Segment leadership reflects long clinical experience, low acquisition cost, and broad generic availability. Beta-blockers also serve as the comparator in ivabradine research, including a propranolol versus ivabradine crossover trial at the University of Calgary.

Ivabradine is anticipated to be the fastest-growing drug class, driven by heart-rate control in patients for whom beta-blockers are unsuitable, such as those with low blood pressure. Growth is supported by lower costs following the launch of AB-rated generic ivabradine tablets by Ingenus, Camber, and Zydus in July 2024, and by additional FDA approvals, including Alembic in November 2024. A randomized trial in hyperadrenergic POTS reported heart rate and quality-of-life benefits, while RECOVER-AUTONOMIC found no significant symptom improvement in Long COVID POTS despite heart rate reduction, which is shaping use toward selected subtypes.

North America Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

North America is anticipated to account for approximately 39.6% of the market share. The region benefits from established autonomic disorder centers, a dedicated diagnosis code, federally funded research, and an active clinical trial ecosystem.

U.S. Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

The United States remains the leading market in North America due to its large diagnosed population, with estimates ranging from 500,000 to 3,000,000 patients, and the highest concentration of POTS research activity. ICD-10-CM code G90.A, effective since October 1, 2022, supports documentation and national-level research. In March 2026, the NIH-funded RECOVER Initiative presented ivabradine trial results from 181 adults with Long COVID POTS at the American College of Cardiology annual conference.

In October 2026, Regeneron reported plans to present Phase 2 results for baloncibart at the American Autonomic Society meeting in November 2026 and to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback. This development reflects the regional shift from repurposed drugs toward POTS-specific therapies.

Europe Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

Europe is a well-established market characterized by publicly funded healthcare systems, strong academic autonomic research, and growing recognition of Long COVID-related POTS. A Karolinska Institutet study published in Circulation: Arrhythmia and Electrophysiology on September 30, 2025 identified POTS in almost one-third of 467 patients with severe Long COVID, compared with less than 1% of the Swedish population before the pandemic.

Germany Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

Germany represents a major European market because of its large population, extensive hospital network, and active Long COVID research base. In 2026, researchers from MediClin's Institute of Rehabilitation Research in Offenburg and partner German universities published a study in the Journal of Rehabilitation Medicine on the NASA Lean Test for detecting postural orthostatic tachycardia in chronic post-COVID patients.

The country's rehabilitation-based care model supports exercise and lifestyle management programs, which aligns with growth in non-pharmacological treatment.

United Kingdom Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

The U.K. remains an important market where PoTS UK and NHS clinics shape awareness and referral pathways. A multicenter study across eight UK Long COVID clinics, published in the Journal of Medical Virology in March 2024, found that 20 of 277 patients (7%) met criteria for PoTS and 21 (8%) had orthostatic hypotension.

In Scotland, PoTS UK estimated that 9,400 people had PoTS before the pandemic. NHS Scotland's interim signposting document, approved in April 2026, describes the evidence base for current management as notably weak and is scheduled for review in December 2026 or on publication of UK consensus guidelines.

Asia Pacific Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

Asia Pacific is anticipated to be the fastest-growing regional market due to high reported adolescent prevalence, expanding pediatric autonomic care, and growing generic drug manufacturing capacity. A nationwide Japanese study published in June 2026 noted a POTS prevalence of 6.8% among adolescents in a large Chinese epidemiological study, compared with 0.2% to 1.0% in Western countries.

China Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

China represents a major growth market because of its large adolescent population and extensive pediatric research on POTS. A large-scale epidemiological study reported POTS prevalence of approximately 6.8% among adolescents. Chinese pediatric studies describe conventional interventions, with metoprolol or midodrine hydrochloride used for recurrent orthostatic symptoms.

Japan Postural Orthostatic Tachycardia Syndrome Treatment Market Trends

Japan represents a distinct market where POTS is managed within the orthostatic dysregulation framework, which affects approximately 10% of junior high and high school students and is a leading cause of school absenteeism. Japanese guidelines recommend midodrine as the first-line pharmacological treatment for orthostatic intolerance, alongside patient education and lifestyle guidance, including fluid intake of 2 L per day.

In June 2026, a nationwide descriptive study from Fukuoka University examined healthcare utilization for orthostatic dysregulation in Japan.

The global postural orthostatic tachycardia syndrome treatment market is fragmented, with competition occurring among generic drug manufacturers, originator cardiovascular companies, and biotechnology developers advancing POTS-specific programs. Because no therapy is approved specifically for POTS, current revenue is concentrated in off-label prescribing of generic beta-blockers, midodrine, fludrocortisone, and ivabradine. Major companies compete based on abbreviated new drug application portfolios, manufacturing scale, supply reliability, pricing, and distribution reach. Midodrine alone is supplied in the United States by multiple generic manufacturers, including Viatris, Upsher-Smith, Apotex, Zydus, Alembic, and Aurobindo.

Leading companies are focusing on generic portfolio expansion, supply continuity, and clinical development in defined POTS subtypes. Competitive differentiation increasingly depends on the ability to generate randomized evidence in subtype-specific populations, as shown by Regeneron's POTS-specific Phase 2 program and the immune-directed studies sponsored by argenx. Advocacy-funded programs, including Dysautonomia International's POTS Research Fund, are also generating evidence on intravenous immunoglobulin, plasmapheresis, and vagus nerve stimulation.

Key Industry Developments

• In October 2026, Regeneron Pharmaceuticals announced plans to report Phase 2 results for baloncibart, an NPR1 antagonist antibody, in POTS at the American Autonomic Society meeting in November 2026 and to initiate a Phase 3 study in the first half of 2027, pending regulatory feedback, marking a move toward POTS-specific biologic therapy.
• In March 2026, the NIH-funded RECOVER Initiative presented RECOVER-AUTONOMIC (Ivabradine) results at the American College of Cardiology annual conference, showing heart rate reduction versus placebo in 181 adults with Long COVID POTS without significant symptom improvement.